Presentation by Michael Seewald, Michael Seewald, Ph.D. Global Head Evidence, AstraZeneca Biopharmaceuticals for mHealth Israel, October 19th, 2021. Real-World Data is able to uncover local unmet medical need – Call to action to build Learning Healthcare Systems. Significant Variations in Care and Large Potential for Improvement. Real-World Data helps to benchmark efficient use of resources and detect “waste”. Healthcare systems need to address the problem of waste. But fundamental change is hard, and progress slow. Outcomes Transparency Improves ComplianceExample: Swedish myocardial infarction registry. Outcomes Transparency Improves Compliance. Example: Swedish myocardial infarction registry. Improving Outcomes and Creating Value will continue to guide Learning Healthcare Systems- enabled by RWD. Four technological trends as accelerators on our path. Empowered patients- Molecular screening and 24/7 monitoring driving a step change in diagnosis. Algorithmic decision-making: Artificial intelligence supports physician intelligence. Evidence-generating healthcare systemsLive insights on clinical efficacy from digital monitoring. 360° care delivery. Home replaces hospital via digital therapeutics and on-demand remote support. AstraZeneca Areas of Partnering Interest: (https://www.astrazeneca.com/partnering/our-areas-of-partnering-interest.html).

1. Real-World Data – What’s Next?
Michael Seewald, Ph.D.
Global Head Evidence
AstraZeneca Biopharmaceuticals
19 October 2021

2.  These slides are based on publicly available information
 The views presented are the views of the presenter, not necessarily
those of AstraZeneca
 These slides are intended for educational purposes only and for the
personal use of the audience. These slides are not intended for wider
distribution outside the intended purpose without speaker approval
 The content of this slide deck is accurate to the best of the presenter’s
knowledge at the time of production
Disclaimer

3. Real-World Data is able to uncover local unmet medical
need – Call to action to build Learning Healthcare Systems
10.2
9.9
9.1
7.8
7.6
3.9
2.9
5.6
X3
Death during first admission for heart failure, %
Source: The EuroHeart Failure survey programme, European Heart Journal (2003) 24, 442–463
6.9
3.5
Significant Variations in Care and Large Potential for Improvement:

4. 4
Real-World Data helps to benchmark efficient use of
resources and detect “waste”
1 US healthcare waste estimated by Berwick D., Hackbarth A., Eliminating Waste in US Health Care. JAMA. 2012;307(14):1513-1516. Pharmaceutical spend based on 2017
estimates in Keehan S et al,, National Health Expenditure Projections, 2016–25: Price Increases, Aging Push Sector To 20 Percent Of Economy, Health Affairs February
2017. Some portion of the pharmaceutical spend could also be included in the estimated waste.
US healthcare spend estimates1 Only 10% of US covered lives in ACOs
Healthcare systems need to
address the problem of waste
But fundamental change is hard,
and progress slow
20-40%
Pharmaceutical
spend
10%
Other
healthcare
costs
60%
Waste
(estimated)

5. 5
Outcomes Transparency Improves Compliance
Example: Swedish myocardial infarction registry
2
3
4
5
6
2005 2006 2007 2008 2009
+13%
+22%
+7%
+40%
RIKS-HIA Quality index
All hospitals (n=69)
Data made public
Bottom half 2007 (n=34)
RIKS-HIA: Register of Information and Knowledge about Swedish Heart Intensive Care Admissions
Source: SWEDEHEART (https://www.ucr.uu.se/swedeheart/)

6. 6
Outcomes Transparency Improves Compliance
Example: Swedish myocardial infarction registry
2
3
4
5
6
2005 2006 2007 2008 2009
+13%
+22%
+7%
+40%
RIKS-HIA Quality index
All hospitals (n=69)
Data made public
Bottom half 2007 (n=34)
RIKS-HIA: Register of Information and Knowledge about Swedish Heart Intensive Care Admissions
Source: SWEDEHEART (https://www.ucr.uu.se/swedeheart/)

7. Transparent outcomes data
1
Analyze
variation
2
Identify
current
best
practices
3
Change
behavior
4
Feedback
and
learning
5
Improving Outcomes and Creating Value will continue to
guide Learning Healthcare Systems- enabled by RWD
Value
 RWD to help quanitfy
 Improved Outcomes
~Guideline adoption
 Use of resources

8. Four technological trends as accelerators on our path
360° care delivery
Home replaces hospital
via digital therapeutics
and on-demand remote
support
Empowered patients
Molecular screening and
24/7 monitoring driving a
step change in diagnosis
Algorithmic
decision-making
Artificial intelligence supports
physician intelligence
Evidence-generating
healthcare systems
Live insights on clinical
efficacy from digital
monitoring

9. AstraZeneca Areas of Partnering Interest
https://www.astrazeneca.com/partnering/our-areas-of-partnering-interest.html

10. Q&A